Leaderboards/COVID-19 Clinical Research Studies

COVID-19 Clinical Research Studies

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Kristen Earle
Bill & Melinda Gates Foundation
2
Timothy A. Bates
Oregon Health & Science University
3
Toni Delorey
Broad Institute
4
Kailin Yin
Nanjing University of Chinese Medicine
5
Emily Stephenson
Newcastle University
6
Ezgi Hacisuleyman
Rockefeller University
7
Panke Qu
The Ohio State University
8
Daniel Wendisch
Charité - Universitätsmedizin Berlin
9
Matan Levine-Tiefenbrun
Tel Aviv University
10
Piyada Supasa
University of Oxford

Papers

1
Publication in Nature Immunology (2024) [341 citations, W4390750996]
Nature Immunology|2024
341 cit.
2
Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants
Cell|2024
159 cit.
3
Neuronal activity rapidly reprograms dendritic translation via eIF4G2:uORF binding
Nature Neuroscience|2024
47 cit.
4
Publication in eLife (2024) [14 citations, W4399075733]
eLife|2024
14 cit.
5
Publication in Biosensors (2026) [3 citations, W7130927252]
Biosensors|2026
3 cit.
6
Temporal multi-omics analysis of COVID-19 in end-stage kidney disease
Cell Genomics|2025
2 cit.
7
Publication in JCI Insight (2025) [2 citations, W4412537856]
JCI Insight|2025
2 cit.
8
Publication in Translational Cancer Research (2026) [W7126089483]
Translational Cancer Research|2026
0 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Jennifer M. McGoogan
Chinese Center For Disease Control and Prevention
2
Lei Liu
Hunan Agricultural University
3
Yuanyuan Zhang
Westlake University
4
Davide Corti
Vir Biotechnology (Switzerland)
5
Daniela Weiskopf
Federal Office for Radiation Protection
6
Xiangxi Wang
Peking University
7
Hong Shan
Sun Yat-sen University
8
Timothée Bruel
Institut Pasteur
9
Quentin Philippot
Inserm
10
Jérémie Rosain
Inserm

Papers

1
Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron
Cell|2022
470 cit.
2
Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies
Nature Medicine|2022
309 cit.
3
Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants
Nature|2022
195 cit.
4
Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75
Cell Host & Microbe|2022
188 cit.
5
Human IRF1 governs macrophagic IFN-γ immunity to mycobacteria
Cell|2023
115 cit.
6
Human IL-23 is essential for IFN-γ–dependent immunity to mycobacteria
Science Immunology|2023
68 cit.
7
Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies
Cell Reports Medicine|2022
58 cit.
8
A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2
Protein & Cell|2024
41 cit.
9
RNA Helicase DDX24 Stabilizes LAMB1 to Promote Hepatocellular Carcinoma Progression
Cancer Research|2022
37 cit.
10
Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia
Journal of Clinical Immunology|2023
33 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Bin Cao
Shandong Provincial Hospital
2
Wenjie Tan
Sinopec (China)
3
Nanshan Zhong
State Key Laboratory of Respiratory Disease
4
Zheng‐Li Shi
Chinese Academy of Sciences
5
Hua Chen
Second Military Medical University
6
Stefan Pöhlmann
German Primate Center
7
Jianwei Wang
Zhejiang Cancer Hospital
8
Fu‐Sheng Wang
National Clinical Research Center for Digestive Diseases
9
Kwok‐Yung Yuen
University of Hong Kong - Shenzhen Hospital
10
Fang Li
Second Affiliated Hospital of Zhengzhou University

Papers

1
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
The Lancet|2020
51.8k cit.
2
Clinical Characteristics of Coronavirus Disease 2019 in China
New England Journal of Medicine|2020
31.2k cit.
3
A Novel Coronavirus from Patients with Pneumonia in China, 2019
New England Journal of Medicine|2020
30.4k cit.
4
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
The Lancet|2020
29.1k cit.
5
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Nature|2020
23.3k cit.
6
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Cell|2020
21.4k cit.
7
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
The Lancet|2020
12.6k cit.
8
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
The Lancet Respiratory Medicine|2020
8.9k cit.
9
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
New England Journal of Medicine|2020
5.5k cit.
10
Detection of SARS-CoV-2 in Different Types of Clinical Specimens
JAMA|2020
5.3k cit.

Reagents for COVID-19 Clinical Research Studies

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Thermo Fisher ScientificEvidence 77

CD28 Monoclonal Antibody (10F3)

Cited in 29 papers
#CD2800-4
View Evidence →
Thermo Fisher ScientificEvidence 79

CD64 Monoclonal Antibody (10.1), PE

Cited in 29 papers
#CD6404-4
View Evidence →
Thermo Fisher ScientificEvidence 78

CD61 Monoclonal Antibody (F11), PE

Cited in 29 papers
#CD6104-4
View Evidence →

🌟 All-Time

Most validated

Cell Signaling TechnologyEvidence 66

GPNMB (E7U1Z) Feline Chimeric Monoclonal Antibody

Cited in 55 papers
#77093$160,354
View Evidence →
Cell Signaling TechnologyEvidence 65

Phospho-SHP-2 (Tyr542) (E8D6V) Rabbit Monoclonal Antibody (BSA and Azide Free)

Cited in 31 papers
#94740$898
View Evidence →
Thermo Fisher ScientificEvidence 73

CD2 Monoclonal Antibody (S5.5), FITC

Cited in 29 papers
#CD0201-4
View Evidence →